Abstract 3-Hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase catalyzes the formation of mevalonate, an essential precursor for isoprenoid compounds in mammalian cells. Recent studies have shown that mevinolin, a competitive inhibitor of the reductase, inhibits cell proliferation and induces differentiation in cultured C1300 (Neuro-2A) murine neuroblastoma cells. We now report that mevinolin can inhibit neuroblastoma growth in vivo. The specific activity of HMG-CoA reductase in subcutaneous neuroblastomas increased more than 20-fold between the fifth and eighth days after tumor inoculation, and remained elevated for the remainder of the tumor lifetime in mice. The increase in reductase activity was correlated with a marked increase in tumor DNA content and exponential increase in tumor weight. Using an in vitro assay to monitor the ability of mouse serum to suppress sterol synthesis, we determined that mevinolin was inactivated or cleared from the circulation within 3-6 h after a single subcutaneous injection. However, by using subcutaneous osmotic pumps to deliver a constant infusion of mevinolin, we were able to maintain adequate blood levels of the drug for 7 d. Mevinolin (5 mg/kg per h) suppressed tumor growth (wet weight) significantly when treatment was carried out between day 1 and day 8 or between day 5 and day 12 after tumor inoculation. Histopathological examination of tumors from mevinolin-treated mice revealed few or no mitotic figures and marked cellular degeneration. Measurements of incorporation of (3H)acetate into neuroblastoma sterols and ubiquinones 24 h after implantation of osmotic pumps showed that mevinolin produced a marked inhibition of isoprenoid synthesis in the tumors in vivo. The data suggest that, in addition to their demonstrated utility as cholesterol-lowering drugs, competitive inhibitors of HMG-CoA reductase may have considerable potential as novel antineoplastic agents.
Introduction
Mevalonate is an essential precursor of various cellular isoprenoid compounds including cholesterol (1) , dolichol (2, 3), ubiquinone (coenzyme Q) (4, 5) , isopentenyl-transfer RNA (tRNA) (6, 7) , and recently discovered isoprenoid proteins (8) . The formation of mevalonate, which is catalyzed by 3-hydroxy-3-meth-ylglutaryl coenzyme A (HMG-CoA)' reductase, has long been regarded as the major regulatory step for de novo cholesterol biosynthesis (9-1 1). For this reason, competitive inhibitors of HMG-CoA reductase, such as compactin (ML 236B) (12) and mevinolin (MK803) (13) , have received much attention as potential new therapeutic agents for treatment of hypercholesterolemia (14) (15) (16) (17) (18) (19) (20) (21) . In addition to their cholesterol-lowering activity in vivo, these inhibitors ofmevalonate synthesis exhibit cytostatic activity when added to proliferating cells in tissue culture (22) (23) (24) (25) (26) (27) . Recent studies in this laboratory have shown that mevinolin also induces morphological and biochemical differentiation in cultured murine neuroblastoma cells (27) . These observations, together with the fact that many malignant tissues exhibit relatively high activities of HMG-CoA reductase (28) (29) (30) (31) (32) (33) , suggested that selective inhibition of this enzyme might be exploited as a novel approach to cancer chemotherapy. Using the C1300 (Neuro-2A) murine neuroblastoma as a model system, we have shown that mevinolin effectively suppresses tumor growth in vivo.
Methods
Materials. [I-'4C]Acetic acid, sodium salt (57 mCi/mmol) was purchased from Amersham Corp., Arlington Heights, IL, and [3H]acetic acid, sodium salt (100 mCi/mmol) was obtained from New England Nuclear, Boston, MA. Tissue culture medium and fetal calf serum were obtained from Gibco Laboratories, Grand Island, NY. Osmotic pumps for constant-infusion drug delivery (Model 2001) were purchased from Alza Corp., Palo Alto, CA. All other chemicals were from Sigma Chemical Co., St. Louis, MO. Tumor inoculations. C 1300 (Neuro-2A) murine neuroblastoma cells were obtained from the American Type Culture Collection (Rockville, MD) and maintained in monolayer culture as described previously (27 (37, 38) . The chloroform phase was evaporated under nitrogen and the lipids were separated by two-dimensional thin-layer chromatography on Silica Gel G-25, 20 X 20 cm plates (Brinkman Instruments Co.), using solvent systems of hexane/diethyl ether/glacial acetic acid (70:30:1.5, vol/vol/vol) for the first dimension and benzene for the second dimension. The lipids were visualized by briefexposure ofthe plates to iodine vapor, and the zones corresponding to the lipid standards were scraped into scintillation vials and counted with 10 ml Econofluor (New England Nuclear, Boston, MA). Samples were counted in a Packard Tri-Carb liquid scintillation spectrometer (model 3255), and the counting efficiency was determined by the external standards channel ratio method. Results were expressed as disintegrations per minute incorporated into the lipid zone per gram of protein in the extracted homogenate. Alternatively, to normalize data for possible losses of material during lipid extraction, or variations in acetate uptake or pool sizes in the tumors, the incorporation ofradioactivity into the sterol and ubiquinone spots on the thin-layer plates was compared with the radioactivity in the phospholipid zone, which is not decreased by mevinolin (39) .
Histopathology. Tumors were resected in toto and fixed by immersion in buffered 10% formalin. After dividing the tumors into equal halves, the tissues were dehydrated, embedded in paraffin, sectioned at 6 Mm, and stained with hematoxylin and eosin.
Results
To determine when the C 1300 murine neuroblastoma might be most vulnerable to inhibitors of HMG-CoA reductase, we first measured the activity ofthe enzyme throughout the growth cycle of subcutaneous tumors. The specific activity of the reductase was low in tumors that were excised after 5 d; however, between 5 and 8 d the enzyme activity increased more than 20-fold (Fig. 2 B) .
To establish optimal conditions for chemotherapeutic trials of mevinolin in mice, it was necessary to determine how rapidly this compound is cleared from the circulation. Groups of mice were given single subcutaneous injections of mevinolin at three different doses and blood was withdrawn from the tail vein at serial intervals after injection. By assaying the ability of 100-M1 samples of mouse serum to suppress the incorporation of [ ml of culture medium (0.5 ,ug/ml of serum) (Fig. 3 A) . Using this bioassay, we found that most ofthe mevinolin derived from a single subcutaneous injection was either inactivated or removed from the circulation within 3-6 h (Fig. 3 B) . To circumvent the problem of rapid clearance of mevinolin in mice, we resorted to the use of surgically-implanted subcutaneous osmotic pumps (Alza Corp.), which can be used to deliver a continuous drug infusion at a constant flow-rate for a period of 7 d (40) . Three experiments were carried out to assess the ability of mevinolin to suppress neuroblastoma growth in mice. In the first two trials, the pumps containing either mevinolin or vehicle solution were implanted on the day after tumor inoculation. After 7 d subcutaneous tumor growth was evident in all of the control mice, whereas tumor development in the mevinolintreated mice was markedly stunted (Table I ). In the third trial, we waited until the fifth day after tumor inoculation before commencing mevinolin treatment. Again, significant inhibition oftumor growth, based on tumor wet weight, was observed after 7 d of mevinolin treatment (12 d after tumor inoculation) ( Table I ).
The tumors removed from control mice and mice treated with 5 mg/kg per h mevinolin (Trial III, Table I ) were examined histopathologically. The tumor histology in the four controls was the same. Tumors were densely cellular, malignant, epithelial-looking neoplasms composed of moderately large, polygonal cells with well-defined borders and no definite cell processes. Cells were arranged in sheets and the tumor was bound by a (Table I) , the surface area of the sectioned halves of the dehydrated and embedded tumors from the mevinolin-treated mice was less than one fifth that of the control tumors (Fig. 4) . Concentrated solutions of mevinolin produced some inflammatory injury, necrosis, and subcutaneous edema near the outflow site ofthe osmotic pumps, presumably due to the effects A B aps S .,W" of high local drug levels on the dermal and epidermal tissues. However, the mevinolin-treated mice were comparable to the controls with respect to total body weight, liver weight, erythrocyte count, and BUN levels (Table I) . Upon gross examination, the internal organs (e.g., heart, lungs, spleen, gastrointestinal tract) appeared normal. Total leukocyte counts also fell within the normal range; however, differential counts revealed an increased proportion of granulocytes (almost exclusively neutrophils) relative to lymphocytes in the mevinolin-treated animals. This probably reflects a stimulation ofgranulopoiesis in response to the local skin injury near the pump site, rather than a direct effect of mevinolin. In any case, the data suggest that mevinolin does not suppress the proliferative response of the granulopoietic and erythropoietic stem cells. Finally, we detected no obvious signs of neurotoxicity, such as ataxia, dystonia, or paralysis, in the mice treated with mevinolin.
Competitive inhibitors of HMG-CoA reductase are known to produce compensatory increases in the content ofthis enzyme in mouse liver (42, 43) , rat hepatocytes (44), Chinese hamster ovary cells (45) , and cultured human skin fibroblasts (46) . We have observed a similar increase in the activity of HMG-CoA reductase in broken-cell preparations from neuroblastoma cultures exposed to mevinolin for 24 h (Maltese, W. A., and K. M. Sheridan, unpublished observation). However, as long as the competitive inhibitor is present in the culture medium, isoprenoid synthesis remains blocked in the intact neuroblastoma cells (39) . Serum samples obtained from the mevinolin-treated mice at the end of the 7-d treatment regimen contained substantial sterol synthesis-suppressing activity in vitro ( Table I ), indicating that the osmotic pumps had delivered mevinolin for the duration of the study. However, to determine whether the level ofcirculating mevinolin was sufficient to block the activity of HMG-CoA reductase continuously in tumors growing in vivo, we measured the incorporation of [3H]acetate into neuroblastoma sterols in mice that had been treated with a continuous infusion of mevinolin for 24 h. As shown in Table II , the level of mevinolin generated by the osmotic pumps resulted in an 80% decrease in the relative rate of sterol synthesis in the tumors. The decreased labeling of ubiquinone (Table II) Table I ) and from the four mice treated with mevinolin at a dose of 5 mg/kg per h in the same group. All photographs show sections stained with hematoxylin-eosin and magnified X1.3.
Suppression ofTumor Growth by Mevinolin 1751 Six mice were inoculated with neuroblastoma cells on day 0 and subcutaneous tumors were allowed to develop for 10 d. On the 11th day after tumor inoculation osmotic pumps containing mevinolin or vehicle solution were implanted. 24 h later, the mice were given an intraperitoneal injection of [3H]acetate (50 mCi/kg) and tumors were removed after 2 h. The incorporation of radioactivity into lipids comigrating with cholesterol (C), ubiquinone-IO (U), and phospholipids (PL) was determined as described in the Methods. All values are mean±SEM.
the level of circulating mevinolin was also sufficient to inhibit the flux ofacetate into other branches ofthe isoprenoid pathway that normally seem to be saturated at low mevalonate concentrations (1) .
Discussion
The present study shows that continuous infusion of mevinolin, a competitive inhibitor of HMG-CoA reductase, inhibits the growth of neuroblastoma in mice. The histopathology of the mevinolin-treated neuroblastomas suggests that the effects of mevinolin in vivo are similar to those observed in cultured cells after blocking mevalonate synthesis; i.e., initial arrest ofcell proliferation (22-27) followed by eventual cell death (47) . However, since foci of spontaneous degeneration were observed in the untreated tumors, it remains possible that the stunted growth of the treated tumors reflects, at least in part, attrition in the absence of new cell growth, rather than a direct cytocidal effect ofthe drug. The general absence ofovert toxicity in mice treated with mevinolin for 7 d is consistent with the results ofpreliminary clinical trials in which much lower doses of this compound, administered twice daily for 1-4 wk, were found to have a cholesterol-lowering effect in normal volunteers or patients with hypercholesterolemia without producing major adverse side effects (17) (18) (19) (20) . Our observation that the serum cholesterol levels in the mice treated with mevinolin were not reduced (Table I) , is consistent with an earlier report that the mevinolin analog, compactin, is not an effective hypocholesterolemic drug in mice and rats (42) . Endo et al. (42) proposed that this phenomenon might be due to the fact that compactin decreases the elimination of hepatic cholesterol via the bile acid pathway in rodents, but not in dogs or primates. However, because the animals in their study were given only one dose of compactin per day, it was also possible that rapid drug clearance and subsequent expression of induced hepatic HMG-CoA reductase activity contributed to the lack of hypocholesterolemic activity (42). Although we did not measure hepatic sterol synthesis, our finding that normal serum cholesterol levels were maintained in mice receiving a constant infusion of mevinolin at a dose sufficient to block the induced HMGCoA reductase activity in subcutaneous tumors (Table II) suggests that the latter mechanism (i.e., expression of induced hepatic HMG-CoA reductase) was not the primary cause for the ineffectiveness of mevinolin as a cholesterol-lowering agent in our experiments. In any case, the observation that mevinolin inhibited tumor growth without decreasing serum cholesterol levels has important implications for the possible mechanism underlying the antineoplastic activity of this compound. Thus, since murine neuroblastoma cells can utilize extracellular serum low-density lipoprotein as a source of cholesterol (34, 48) , it seems unlikely that inhibition of de novo sterol synthesis by mevinolin could by itself deprive the growing tumor cells of cholesterol needed for membrane replication. On the other hand, the data demonstrating a decreased incorporation of [3H]acetate into ubiquinone in tumors from mevinolin-treated mice (Table  II) are provocative, since they suggest that inhibition of neuroblastoma growth may be related to inhibition of the synthesis ofnonsterol isoprenoid compounds such as dolichol, ubiquinone, isopentenyl-tRNA, or other poorly characterized isoprenoids that are required by rapidly proliferating cells. This conclusion would be consistent with studies of synchronized cells in vitro, which have shown that supplementing the cultures with cholesterol cannot reverse the arrest of cell proliferation that occurs when mevalonate synthesis is blocked by high concentrations of compactin or mevinolin (23) (24) (25) (26) .
The C1300 murine neuroblastoma is considered to be a good model for human neuroblastoma, insofar as it exhibits a similar pattern of metastasis (49) and is relatively resistant to most conventional chemotherapeutic drugs targeted at DNA replication (50) (51) (52) . Therefore, although much remains to be learned about the effects of mevinolin on long-term survival, tumor metastasis, and the physiology of normal tissues, our observation that this compound can suppress tumor growth in vivo suggests that competitive inhibitors of HMG-CoA reductase merit serious evaluation as potential chemotherapeutic agents for treatment of neuroblastoma and other malignancies (32) exhibiting relatively high levels of this enzyme.
